NOT-HD-14-025: Notice of NICHD's Participation in PAR-14-254 "Multidisciplinary Studies of HIV and Viral Hepatitis Co-Infection (R21)"

Notice of NICHD's Participation in PAR-14-254 "Multidisciplinary Studies of HIV and Viral Hepatitis Co-Infection (R21)"

Notice Number: NOT-HD-14-025

Key Dates
Release Date: July 30, 2014

Related Announcements
PAR-14-254

Issued by
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Purpose

The purpose of this Notice is to inform potential applicants of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)'s participation, effective immediately, in PAR-14-254 "Multidisciplinary Studies of HIV and Viral Hepatitis Co-Infection (R21)".

The following sections of PAR-14-254 have been updated to reflect the participation of NICHD in this FOA:

Part 1. Overview Information

Components of Participating Organizations
National Institute of Allergy and Infectious Diseases (NIAID)
National Cancer Institute (NCI)
Eunice Kennedy ShriverNational Institute of Child Health and Human Development (NICHD)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute on Drug Abuse (NIDA)
National Institute of Mental Health (NIMH)

Catalog of Federal Domestic Assistance (CFDA) Number(s)
93.855, 93.856, 93.393, 93.394, 93.395, 93.396, 93.273, 93.847, 93.279, 93.242, 93.399, 93.865

Part 2. Section 1. Funding Opportunity Description

Specific Areas of Research Interest
Additional examples of NIH-funded programs funded by NICHD include the Pediatric HIV AIDS Cohort Study (PHACS) and NICHD International Site Development Initiative (NISDI).

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Studies of NICHD target populations: pregnant/postpartum women, adolescents, children, and infants with HIV-HBV or HIV-HCV coinfection and of infants born to women with HIV-HBV or HIV-HCV coinfection.
To study host and risk factors and mechanisms associated with spontaneous clearance of HCV and sustained virologic response to HCV or HBV treatment in NICHD target populations;
To identify host and risk factors and mechanisms associated with co-morbidity (e.g., more rapid liver disease progression) in NICHD target populations;
To study factors associated with acquisition of HBV or HCV in HIV-infected pregnant women, adolescents, children and infants or acquisition of HIV in HBV- or HCV-infected pregnant women, adolescents, children and infants;
To identify predictors for HBV or HCV perinatal transmission in HIV-co-infection;
To study effectiveness of interferon-free direct-acting antiviral drug regimens to treat HIV/HCV co-infection in NICHD target populations.

Part 2. Section VII. Agency Contacts

Scientific/Research Contact
George K. Siberry, MD, MPH
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Telephone: 301- 496-7350
Email: [email protected]

Financial/Grants Management Contact
Bryan S. Clark, MBA
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Telephone: 301-435-6975
Email: [email protected]

All other aspects of this FOA remain the same.

Inquiries

Please direct all inquiries to:

George K. Siberry, MD, MPH
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Telephone: 301- 496-7350
Email: [email protected]